COST EFFECTIVENESS ANALYSIS OF LENVATINIB FOR THE FIRST-LINE TREATMENT OF INDIVIDUALS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA

Author(s)

Li X1, Wudong G2, Wang Y2
1National Health Commission, Beijing, China, 2China National Health Development Research Center, Beijing, China

OBJECTIVES : Liver cancer is the most common cancer with limited treatment options for patients at advanced stage. Lenvatinib was proved to be non-inferior compared to the only targeted cancer drug sorafenib for the treatment of unresectable hepatocellular carcinoma (HCC) in the Phase III REFLECT trial. This study was to develop a cost-effectiveness model of lenvatinib for the first-line treatment of unresectable hepatocellular carcinoma (HCC) in China based on data from REFELECT trail.

METHODS : A partitioned survival model (PSM) was developed with the following health states: progression-free, progressed and dead. The time horizon of the model was life time with payer’s perspective in China. Efficacy and safety data were extracted from the REFLECT trial. Utility values were derived from the European Quality-of-Life 5-Dimension Questionnaire, conducted with patients enrolled in the REFLECT trial. Direct medical costs were obtained from 8 hospitals located in eastern, middle and western China. Deterministic and probabilistic sensitivity analyses were performed.

RESULTS : The incremental cost-effectiveness ratio (ICER) for lenvatinib versus sorafenib was ¥ 633,212 per quality-adjusted life year (QALY) gained.

CONCLUSIONS : Lenvatinib is not expected to be a cost-effective use in healthcare system in China, assuming a cost-effectiveness threshold of 3 times per capita GDP per QALY, which is 216,600 RMB.

Conference/Value in Health Info

2020-05, ISPOR 2020, Orlando, FL, USA

Value in Health, Volume 23, Issue 5, S1 (May 2020)

Code

PCN77

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Drugs, Oncology

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×